Jeff Alder
Bayer (United States)(US)
Publications by Year
Research Areas
Antimicrobial Resistance in Staphylococcus, Bacterial Identification and Susceptibility Testing, Pneumonia and Respiratory Infections, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria
Most-Cited Works
- → Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections(2005)559 cited
- → Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact(2005)534 cited
- → Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus(2006)454 cited
- → Bactericidal Action of Daptomycin against Stationary-Phase and Nondividing Staphylococcus aureus Cells(2007)277 cited
- → Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin(2006)261 cited
- → Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study(2012)200 cited
- → Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community‐Acquired Pneumonia(2008)160 cited
- → Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus(2003)135 cited
- → Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial(2019)127 cited
- → A comprehensive regulatory framework to address the unmet need for new antibacterial treatments(2013)119 cited